Cargando…

A VISION Substudy of Reader Agreement on (68)Ga-PSMA-11 PET/CT Scan Interpretation to Determine Patient Eligibility for (177)Lu-PSMA-617 Radioligand Therapy

[ (68)Ga]Ga-PSMA-11 ( (68)Ga-PSMA-11) is used to identify prostate-specific membrane antigen (PSMA)–positive tumors on PET scans. In the VISION study, (68)Ga-PSMA-11 was used to determine the eligibility of patients with metastatic castration-resistant prostate cancer for treatment with [(177)Lu]Lu-...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuo, Phillip H., Yoo, Don C., Avery, Ryan, Seltzer, Marc, Calais, Jeremie, Nagarajah, James, Weber, Wolfgang A., Fendler, Wolfgang P., Hofman, Michael S., Krause, Bernd J., Brackman, Marcia, Kpamegan, Euloge, Ghebremariam, Samson, Benson, Taylor, Catafau, Ana M., Kendi, Ayse T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Society of Nuclear Medicine 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394308/
https://www.ncbi.nlm.nih.gov/pubmed/37230533
http://dx.doi.org/10.2967/jnumed.122.265077
_version_ 1785083344298442752
author Kuo, Phillip H.
Yoo, Don C.
Avery, Ryan
Seltzer, Marc
Calais, Jeremie
Nagarajah, James
Weber, Wolfgang A.
Fendler, Wolfgang P.
Hofman, Michael S.
Krause, Bernd J.
Brackman, Marcia
Kpamegan, Euloge
Ghebremariam, Samson
Benson, Taylor
Catafau, Ana M.
Kendi, Ayse T.
author_facet Kuo, Phillip H.
Yoo, Don C.
Avery, Ryan
Seltzer, Marc
Calais, Jeremie
Nagarajah, James
Weber, Wolfgang A.
Fendler, Wolfgang P.
Hofman, Michael S.
Krause, Bernd J.
Brackman, Marcia
Kpamegan, Euloge
Ghebremariam, Samson
Benson, Taylor
Catafau, Ana M.
Kendi, Ayse T.
author_sort Kuo, Phillip H.
collection PubMed
description [ (68)Ga]Ga-PSMA-11 ( (68)Ga-PSMA-11) is used to identify prostate-specific membrane antigen (PSMA)–positive tumors on PET scans. In the VISION study, (68)Ga-PSMA-11 was used to determine the eligibility of patients with metastatic castration-resistant prostate cancer for treatment with [(177)Lu]Lu-PSMA-617 ((177)Lu-PSMA-617), based on predefined read criteria. This substudy aimed to investigate the interreader variability and intrareader reproducibility of visual assessments of (68)Ga-PSMA-11 PET/CT scans using the VISION read criteria and evaluate the agreement between read results for this and the VISION study. Methods: In VISION, (68)Ga-PSMA-11 PET/CT scans were centrally read as inclusion cases if they had at least 1 PSMA-positive lesion and no PSMA-negative lesions that fulfilled the exclusion criteria. In this substudy, 125 PET/CT scans (75 inclusion and 50 exclusion cases) were randomly selected from VISION and retrospectively assessed by 3 independent central readers. A random subset of 20 cases (12 inclusion and 8 exclusion cases) was recoded for assessment of intrareader reproducibility. Classification of cases as inclusion or exclusion cases was based on the VISION read criteria. Overall interreader variability was assessed by Fleiss κ-statistics, and pairwise variability and intrareader reproducibility were assessed by Cohen κ-statistics. Results: For interreader variability, the readers agreed on 77% of cases (overall average agreement rate, 0.85; Fleiss κ, 0.60 [95% CI, 0.50–0.70]). The pairwise agreement rate was 0.82, 0.88, and 0.84, and the corresponding Cohen κ was 0.54 (95% CI, 0.38–0.71), 0.67 (95% CI, 0.52–0.83), and 0.59 (95% CI, 0.43–0.75), respectively. For intrareader reproducibility, the agreement rate was 0.90, 0.90, and 0.95, and the corresponding Cohen κ was 0.78 (95% CI, 0.49–0.99), 0.76 (95% CI, 0.46–0.99), and 0.89 (95% CI, 0.67–0.99), respectively. The number of actual VISION inclusion cases out of the total number of cases scored as inclusion in this substudy was 71 of 93 (agreement rate, 0.76; 95% CI, 0.66–0.85) for reader 1, 70 of 88 (0.80; 0.70–0.87) for reader 2, and 73 of 96 (0.76; 0.66–0.84) for reader 3. All readers agreed on 66 of 75 VISION inclusion cases. Conclusion: Moderate-to-substantial interreader agreement and substantial-to-almost perfect intrareader reproducibility for (68)Ga-PSMA-11 PET/CT scan assessment using the VISION read criteria were observed. The read rules applied in VISION can be readily learned and demonstrate good reproducibility.
format Online
Article
Text
id pubmed-10394308
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Society of Nuclear Medicine
record_format MEDLINE/PubMed
spelling pubmed-103943082023-08-03 A VISION Substudy of Reader Agreement on (68)Ga-PSMA-11 PET/CT Scan Interpretation to Determine Patient Eligibility for (177)Lu-PSMA-617 Radioligand Therapy Kuo, Phillip H. Yoo, Don C. Avery, Ryan Seltzer, Marc Calais, Jeremie Nagarajah, James Weber, Wolfgang A. Fendler, Wolfgang P. Hofman, Michael S. Krause, Bernd J. Brackman, Marcia Kpamegan, Euloge Ghebremariam, Samson Benson, Taylor Catafau, Ana M. Kendi, Ayse T. J Nucl Med Clinical Investigation [ (68)Ga]Ga-PSMA-11 ( (68)Ga-PSMA-11) is used to identify prostate-specific membrane antigen (PSMA)–positive tumors on PET scans. In the VISION study, (68)Ga-PSMA-11 was used to determine the eligibility of patients with metastatic castration-resistant prostate cancer for treatment with [(177)Lu]Lu-PSMA-617 ((177)Lu-PSMA-617), based on predefined read criteria. This substudy aimed to investigate the interreader variability and intrareader reproducibility of visual assessments of (68)Ga-PSMA-11 PET/CT scans using the VISION read criteria and evaluate the agreement between read results for this and the VISION study. Methods: In VISION, (68)Ga-PSMA-11 PET/CT scans were centrally read as inclusion cases if they had at least 1 PSMA-positive lesion and no PSMA-negative lesions that fulfilled the exclusion criteria. In this substudy, 125 PET/CT scans (75 inclusion and 50 exclusion cases) were randomly selected from VISION and retrospectively assessed by 3 independent central readers. A random subset of 20 cases (12 inclusion and 8 exclusion cases) was recoded for assessment of intrareader reproducibility. Classification of cases as inclusion or exclusion cases was based on the VISION read criteria. Overall interreader variability was assessed by Fleiss κ-statistics, and pairwise variability and intrareader reproducibility were assessed by Cohen κ-statistics. Results: For interreader variability, the readers agreed on 77% of cases (overall average agreement rate, 0.85; Fleiss κ, 0.60 [95% CI, 0.50–0.70]). The pairwise agreement rate was 0.82, 0.88, and 0.84, and the corresponding Cohen κ was 0.54 (95% CI, 0.38–0.71), 0.67 (95% CI, 0.52–0.83), and 0.59 (95% CI, 0.43–0.75), respectively. For intrareader reproducibility, the agreement rate was 0.90, 0.90, and 0.95, and the corresponding Cohen κ was 0.78 (95% CI, 0.49–0.99), 0.76 (95% CI, 0.46–0.99), and 0.89 (95% CI, 0.67–0.99), respectively. The number of actual VISION inclusion cases out of the total number of cases scored as inclusion in this substudy was 71 of 93 (agreement rate, 0.76; 95% CI, 0.66–0.85) for reader 1, 70 of 88 (0.80; 0.70–0.87) for reader 2, and 73 of 96 (0.76; 0.66–0.84) for reader 3. All readers agreed on 66 of 75 VISION inclusion cases. Conclusion: Moderate-to-substantial interreader agreement and substantial-to-almost perfect intrareader reproducibility for (68)Ga-PSMA-11 PET/CT scan assessment using the VISION read criteria were observed. The read rules applied in VISION can be readily learned and demonstrate good reproducibility. Society of Nuclear Medicine 2023-08 /pmc/articles/PMC10394308/ /pubmed/37230533 http://dx.doi.org/10.2967/jnumed.122.265077 Text en © 2023 by the Society of Nuclear Medicine and Molecular Imaging. https://creativecommons.org/licenses/by/4.0/Immediate Open Access: Creative Commons Attribution 4.0 International License (CC BY) allows users to share and adapt with attribution, excluding materials credited to previous publications. License: https://creativecommons.org/licenses/by/4.0/. Details: http://jnm.snmjournals.org/site/misc/permission.xhtml.
spellingShingle Clinical Investigation
Kuo, Phillip H.
Yoo, Don C.
Avery, Ryan
Seltzer, Marc
Calais, Jeremie
Nagarajah, James
Weber, Wolfgang A.
Fendler, Wolfgang P.
Hofman, Michael S.
Krause, Bernd J.
Brackman, Marcia
Kpamegan, Euloge
Ghebremariam, Samson
Benson, Taylor
Catafau, Ana M.
Kendi, Ayse T.
A VISION Substudy of Reader Agreement on (68)Ga-PSMA-11 PET/CT Scan Interpretation to Determine Patient Eligibility for (177)Lu-PSMA-617 Radioligand Therapy
title A VISION Substudy of Reader Agreement on (68)Ga-PSMA-11 PET/CT Scan Interpretation to Determine Patient Eligibility for (177)Lu-PSMA-617 Radioligand Therapy
title_full A VISION Substudy of Reader Agreement on (68)Ga-PSMA-11 PET/CT Scan Interpretation to Determine Patient Eligibility for (177)Lu-PSMA-617 Radioligand Therapy
title_fullStr A VISION Substudy of Reader Agreement on (68)Ga-PSMA-11 PET/CT Scan Interpretation to Determine Patient Eligibility for (177)Lu-PSMA-617 Radioligand Therapy
title_full_unstemmed A VISION Substudy of Reader Agreement on (68)Ga-PSMA-11 PET/CT Scan Interpretation to Determine Patient Eligibility for (177)Lu-PSMA-617 Radioligand Therapy
title_short A VISION Substudy of Reader Agreement on (68)Ga-PSMA-11 PET/CT Scan Interpretation to Determine Patient Eligibility for (177)Lu-PSMA-617 Radioligand Therapy
title_sort vision substudy of reader agreement on (68)ga-psma-11 pet/ct scan interpretation to determine patient eligibility for (177)lu-psma-617 radioligand therapy
topic Clinical Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394308/
https://www.ncbi.nlm.nih.gov/pubmed/37230533
http://dx.doi.org/10.2967/jnumed.122.265077
work_keys_str_mv AT kuophilliph avisionsubstudyofreaderagreementon68gapsma11petctscaninterpretationtodeterminepatienteligibilityfor177lupsma617radioligandtherapy
AT yoodonc avisionsubstudyofreaderagreementon68gapsma11petctscaninterpretationtodeterminepatienteligibilityfor177lupsma617radioligandtherapy
AT averyryan avisionsubstudyofreaderagreementon68gapsma11petctscaninterpretationtodeterminepatienteligibilityfor177lupsma617radioligandtherapy
AT seltzermarc avisionsubstudyofreaderagreementon68gapsma11petctscaninterpretationtodeterminepatienteligibilityfor177lupsma617radioligandtherapy
AT calaisjeremie avisionsubstudyofreaderagreementon68gapsma11petctscaninterpretationtodeterminepatienteligibilityfor177lupsma617radioligandtherapy
AT nagarajahjames avisionsubstudyofreaderagreementon68gapsma11petctscaninterpretationtodeterminepatienteligibilityfor177lupsma617radioligandtherapy
AT weberwolfganga avisionsubstudyofreaderagreementon68gapsma11petctscaninterpretationtodeterminepatienteligibilityfor177lupsma617radioligandtherapy
AT fendlerwolfgangp avisionsubstudyofreaderagreementon68gapsma11petctscaninterpretationtodeterminepatienteligibilityfor177lupsma617radioligandtherapy
AT hofmanmichaels avisionsubstudyofreaderagreementon68gapsma11petctscaninterpretationtodeterminepatienteligibilityfor177lupsma617radioligandtherapy
AT krauseberndj avisionsubstudyofreaderagreementon68gapsma11petctscaninterpretationtodeterminepatienteligibilityfor177lupsma617radioligandtherapy
AT brackmanmarcia avisionsubstudyofreaderagreementon68gapsma11petctscaninterpretationtodeterminepatienteligibilityfor177lupsma617radioligandtherapy
AT kpameganeuloge avisionsubstudyofreaderagreementon68gapsma11petctscaninterpretationtodeterminepatienteligibilityfor177lupsma617radioligandtherapy
AT ghebremariamsamson avisionsubstudyofreaderagreementon68gapsma11petctscaninterpretationtodeterminepatienteligibilityfor177lupsma617radioligandtherapy
AT bensontaylor avisionsubstudyofreaderagreementon68gapsma11petctscaninterpretationtodeterminepatienteligibilityfor177lupsma617radioligandtherapy
AT catafauanam avisionsubstudyofreaderagreementon68gapsma11petctscaninterpretationtodeterminepatienteligibilityfor177lupsma617radioligandtherapy
AT kendiayset avisionsubstudyofreaderagreementon68gapsma11petctscaninterpretationtodeterminepatienteligibilityfor177lupsma617radioligandtherapy
AT kuophilliph visionsubstudyofreaderagreementon68gapsma11petctscaninterpretationtodeterminepatienteligibilityfor177lupsma617radioligandtherapy
AT yoodonc visionsubstudyofreaderagreementon68gapsma11petctscaninterpretationtodeterminepatienteligibilityfor177lupsma617radioligandtherapy
AT averyryan visionsubstudyofreaderagreementon68gapsma11petctscaninterpretationtodeterminepatienteligibilityfor177lupsma617radioligandtherapy
AT seltzermarc visionsubstudyofreaderagreementon68gapsma11petctscaninterpretationtodeterminepatienteligibilityfor177lupsma617radioligandtherapy
AT calaisjeremie visionsubstudyofreaderagreementon68gapsma11petctscaninterpretationtodeterminepatienteligibilityfor177lupsma617radioligandtherapy
AT nagarajahjames visionsubstudyofreaderagreementon68gapsma11petctscaninterpretationtodeterminepatienteligibilityfor177lupsma617radioligandtherapy
AT weberwolfganga visionsubstudyofreaderagreementon68gapsma11petctscaninterpretationtodeterminepatienteligibilityfor177lupsma617radioligandtherapy
AT fendlerwolfgangp visionsubstudyofreaderagreementon68gapsma11petctscaninterpretationtodeterminepatienteligibilityfor177lupsma617radioligandtherapy
AT hofmanmichaels visionsubstudyofreaderagreementon68gapsma11petctscaninterpretationtodeterminepatienteligibilityfor177lupsma617radioligandtherapy
AT krauseberndj visionsubstudyofreaderagreementon68gapsma11petctscaninterpretationtodeterminepatienteligibilityfor177lupsma617radioligandtherapy
AT brackmanmarcia visionsubstudyofreaderagreementon68gapsma11petctscaninterpretationtodeterminepatienteligibilityfor177lupsma617radioligandtherapy
AT kpameganeuloge visionsubstudyofreaderagreementon68gapsma11petctscaninterpretationtodeterminepatienteligibilityfor177lupsma617radioligandtherapy
AT ghebremariamsamson visionsubstudyofreaderagreementon68gapsma11petctscaninterpretationtodeterminepatienteligibilityfor177lupsma617radioligandtherapy
AT bensontaylor visionsubstudyofreaderagreementon68gapsma11petctscaninterpretationtodeterminepatienteligibilityfor177lupsma617radioligandtherapy
AT catafauanam visionsubstudyofreaderagreementon68gapsma11petctscaninterpretationtodeterminepatienteligibilityfor177lupsma617radioligandtherapy
AT kendiayset visionsubstudyofreaderagreementon68gapsma11petctscaninterpretationtodeterminepatienteligibilityfor177lupsma617radioligandtherapy